Literature DB >> 1360669

Tat-responsive region RNA of human immunodeficiency virus type 1 stimulates protein synthesis in vivo and in vitro: relationship between structure and function.

S Gunnery1, S R Green, M B Mathews.   

Abstract

The Tat-responsive region (TAR) sequence is present at the 5' end of human immunodeficiency virus 1 mRNAs and as a cytoplasmic form of 58-66 nucleotides. TAR RNA blocks the activation and autophosphorylation of the double-stranded RNA-activated protein kinase in vitro. We show here that TAR RNA also prevents the double-stranded RNA-mediated inhibition of translation in a cell-free system. Mutagenic and structural analyses of TAR RNA indicate that a stem of at least 14 base pairs is required for this activity, whereas the loop and bulge required for transactivation by Tat are dispensable. Truncation of the RNA to 68 nucleotides results in the loss of translational rescue ability, suggesting that the short cytoplasmic TAR RNA produced by viral transcription in vivo may not have the capability to suppress activation of the kinase. However, because longer TAR transcripts stimulate expression in a transient assay in vivo, the TAR structure at the 5' end of viral mRNAs could still exert this function in cis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1360669      PMCID: PMC50591          DOI: 10.1073/pnas.89.23.11557

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Interactions between double-stranded RNA regulators and the protein kinase DAI.

Authors:  L Manche; S R Green; C Schmedt; M B Mathews
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

2.  The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation.

Authors:  M B Feinberg; D Baltimore; A D Frankel
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

Review 3.  Regulation of HIV-1 gene expression.

Authors:  B R Cullen
Journal:  FASEB J       Date:  1991-07       Impact factor: 5.191

Review 4.  Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities.

Authors:  C E Samuel
Journal:  Virology       Date:  1991-07       Impact factor: 3.616

Review 5.  Regulation of expression of human immunodeficiency virus.

Authors:  G N Pavlakis; B K Felber
Journal:  New Biol       Date:  1990-01

6.  Tat transactivation of the human immunodeficiency virus type 1 promoter is influenced by basal promoter activity and the simian virus 40 origin of DNA replication.

Authors:  M Kessler; M B Mathews
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

7.  Unusual structure of the human immunodeficiency virus type 1 trans-activation response element.

Authors:  R A Colvin; M A Garcia-Blanco
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

Review 8.  Measures and countermeasures in the modulation of initiation factor activities by viruses.

Authors:  N Sonenberg
Journal:  New Biol       Date:  1990-05

9.  Structural requirements of double-stranded RNA for the activation of 2',5'-oligo(A) polymerase and protein kinase of interferon-treated HeLa cells.

Authors:  M A Minks; D K West; S Benvin; C Baglioni
Journal:  J Biol Chem       Date:  1979-10-25       Impact factor: 5.157

10.  Tat-dependent adenosine-to-inosine modification of wild-type transactivation response RNA.

Authors:  L Sharmeen; B Bass; N Sonenberg; H Weintraub; M Groudine
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

View more
  37 in total

Review 1.  Double-stranded RNA-activated protein kinase mediates virus-induced apoptosis: a new role for an old actor.

Authors:  R J Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  Human immunodeficiency virus type 1 tat protein activates transcription factor NF-kappaB through the cellular interferon-inducible, double-stranded RNA-dependent protein kinase, PKR.

Authors:  F Demarchi; M I Gutierrez; M Giacca
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

3.  Analysis of PKR activation using analytical ultracentrifugation.

Authors:  James L Cole
Journal:  Macromol Biosci       Date:  2010-07-07       Impact factor: 4.979

4.  Activation of the protein kinase PKR by short double-stranded RNAs with single-stranded tails.

Authors:  Xiaofeng Zheng; Philip C Bevilacqua
Journal:  RNA       Date:  2004-12       Impact factor: 4.942

Review 5.  Tipping the balance: antagonism of PKR kinase and ADAR1 deaminase functions by virus gene products.

Authors:  Cyril X George; Zhiqun Li; Kristina M Okonski; Ann M Toth; Ying Wang; Charles E Samuel
Journal:  J Interferon Cytokine Res       Date:  2009-09       Impact factor: 2.607

6.  A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function.

Authors:  I Mohr; Y Gluzman
Journal:  EMBO J       Date:  1996-09-02       Impact factor: 11.598

7.  Regulation of the double-stranded RNA-dependent protein kinase PKR by RNAs encoded by a repeated sequence in the Epstein-Barr virus genome.

Authors:  A Elia; K G Laing; A Schofield; V J Tilleray; M J Clemens
Journal:  Nucleic Acids Res       Date:  1996-11-15       Impact factor: 16.971

8.  Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production.

Authors:  Neerja Kaushik; Amartya Basu; Paul Palumbo; Rene L Myers; Virendra N Pandey
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

Review 9.  Translation-targeted therapeutics for viral diseases.

Authors:  J B Harford
Journal:  Gene Expr       Date:  1995

10.  RNA dimerization promotes PKR dimerization and activation.

Authors:  Laurie A Heinicke; C Jason Wong; Jeffrey Lary; Subba Rao Nallagatla; Amy Diegelman-Parente; Xiaofeng Zheng; James L Cole; Philip C Bevilacqua
Journal:  J Mol Biol       Date:  2009-05-13       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.